
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at drug called mogamulizumab (also known as KW-0761) for that has got worse or come back after other treatment.
Peripheral T cell lymphoma (PTCL) is a type of non Hodgkin lymphoma where blood cells called T cells become cancerous.
Doctors often use chemotherapy to treat PTCL, but sometimes it continues to grow, or comes back after treatment has finished. Researchers want to find new treatments to help people in this situation. In this trial, they are looking at a drug called mogamulizumab (pronounced mo-gam-u-liz-oo-mab).
Mogamulizumab is a type of biological therapy called a monoclonal antibody.
The aim of this trial is to find out how well mogamulizumab works for people who have already had other treatment for PTCL.
You may be able to enter this trial if you
You cannot enter this trial if you
This phase 2 trial will recruit about 35 people. Everybody taking part has mogamulizumab. You have it through a drip into a vein, once a week for 4 weeks.
If there are no signs of your lymphoma after the first 4 weeks of treatment (a complete response), you can have mogamulizumab twice a month for the next 2 months. After that, the trial doctor may suggest you carry on having it once a month.
If your lymphoma doesn’t get any worse (stable disease) or gets a bit better (a partial response), you carry on having mogamulizumab. As long as you don’t have bad side effects, you can have it once every 2 weeks for as long as it helps you. If your lymphoma starts to get worse, you will stop the trial treatment.
If your lymphoma gets worse during the first 4 weeks of treatment, you leave the trial. Your doctor will talk to you about other treatment options.
You will see the trial team and have some tests before you start treatment. The tests include
You may also have
The trial team will take photographs of your skin. It will not be possible to identify you from the photos.
You go to hospital once a week for the first 4 weeks of treatment. If you carry on having mogamulizumab for longer, you then go to hospital once every 2 weeks until you stop having the drug.
You have blood tests at each visit. And if you have a rash, the trial team will take more photographs.
During treatment, you have a CT scan every 8 weeks. You may also have more PET scans and bone marrow tests.
When you finish treatment, you go back to see the trial team and have more blood tests, a physical examination and an ECG. A member of the trial team will then contact you by phone to see how you are once a month for 3 months. You have blood tests every 3 months for up to a year.
As mogamulizumab is a new drug, there may be some side effects we don’t know about yet. The most common side effects that are known include
If you develop a skin rash during treatment, the trial team will take more photographs. They will also take a biopsy from the area of skin where the rash is, and another from an area of normal skin. This is so they can check whether the rash is caused by your lymphoma or by the trial drug. If you do get a rash, you will have treatment for it.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor John Radford
Kyowa Hakko Kirin Pharma
Inc
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.